Raptor Pharmaceutical Corp. (Raptor) is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. We focus on underserved patient populations where we can have the greatest potential impact. Raptor is a NASDAQ-listed biopharmaceutical company with a product pipeline that may advance therapeutic options for 10 different indications and includes potential for both product launch and partnering revenue within the next 18 months.

Raptor is listed on the NASDAQ under the symbol RPTP.

Raptor owns or has exclusive licenses that protect its product candidates and drug targeting platforms. To date, our IP portfolio consists of 15 filed and provisional patents. We periodically update information on our Intellectual Property through company press releases. Additional information can be obtained through the USPTO web site (www.uspto.gov).